My watch list  

102 Current news of Qiagen


You can refine your search further. Select from the filter options on the left to narrow down your results.

QIAGEN acquires bioinformatics company

Expanding clinical bioinformatics capabilities in molecular oncology


QIAGEN N.V. announced it has entered into an agreement to acquire N-of-One, Inc., a privately-held U.S. molecular decision support company and pioneer in clinical interpretation services for complex genomic data. The addition of N-of-One will enable QIAGEN to significantly expand its ...


QIAGEN acquires Spanish diagnostics start-up company

QIAGEN enters into agreement to acquire STAT-Dx


QIAGEN N.V. announced it has entered into an agreement to acquire STAT-Dx, a privately-held company developing the next generation of multiplex diagnostics for one-step, fully integrated molecular analysis of common syndromes using a novel system based on real-time PCR technology and proven ...


Settlement of patent infrigment lawsuit

QIAGEN pays Oxford Immunotec for royalty free license


QIAGEN N.V. and Oxford Immunotec Ltd. announced that they have reached a settlement in the lawsuit in the U.S. District Court for the District of Massachusetts in Boston alleging patent infringement in relation to QIAGEN’s QuantiFERON®-TB Gold and QuantiFERON®-TB Gold Plus products. Under terms ...


QIAGEN and CENTOGENE to collaborate in bioinformatics for genetic diseases

Aiding the analysis of hereditary disorders by integrating genomic and clinical databases


QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) and CENTOGENE AG announced a collaboration and co-marketing agreement to provide customers more complete Sample to Insight research and clinical testing solutions in rare genetic diseases. CENTOGENE is a leading rare disease company providing ...


Bristol-Myers Squibb and QIAGEN collaborate

Use of NGS Technology to Develop Gene Expression Profiles for Immuno-Oncology Therapies


Bristol-Myers Squibb Company and QIAGEN have signed an agreement to explore the use of next-generation sequencing (NGS) technology to develop gene expression profiles (GEPs) as predictive or prognostic tools for use with Bristol-Myers Squibb novel immuno-oncology (I-O) therapies in cancer ...


QIAGEN joins CANCER-ID consortium for liquid biopsy workflows

Public-private partnership aims to standardize and clinically validate blood-based biomarkers


QIAGEN N.V. announced it has joined CANCER-ID, a public-private consortium aiming to establish standard protocols and clinical validation for blood-based biomarkers in lung and breast cancer. Rapid advances in the use of liquid biopsies, which enable cancer treatment and monitoring through the ...


QIAGEN enhances bioinformatics portfolio with acquisition of OmicSoft


QIAGEN announced the acquisition of OmicSoft Corporation, providing access to OmicSoft’s powerful multi-omics data management infrastructure solution as well as expertly curated ‘omics’ data sets that complement QIAGEN’s bioinformatics portfolio that are relied upon by customers worldwide to gain ...


QIAGEN comments on preliminary injunction

Confirms intention to defend its U.S. intellectual property position


QIAGEN commented on a decision by the U.S. District Court for the Northern District of California, San Francisco Division, in which the Court granted the motion for a preliminary injunction against the Company as part of patent litigation filed by a competitor. The lawsuit alleges infringement of ...


QIAGEN announces second offer extension for the acquisition of shares in Exiqon A/S

Offer for DKK 18 per share remains valid until 20 June 2016


QIAGEN N.V. announced another extension of the Offer Period for the acquisition of Exiqon A/S, a world leader in RNA technology. On 18 April 2016, QIAGEN N.V. had published a conditional, voluntary public tender offer for the shares in Exiqon A/S, in which the shareholders were offered a cash ...


QIAGEN to submit conditional voluntary takeover offer for shares of Exiqon A/S


QIAGEN N.V. announced that it has decided to submit a conditional voluntary takeover offer to the shareholders of Exiqon A/S to purchase all shares in Exiqon. The acquisition is expected to expand QIAGEN’s leadership position in Sample to Insight solutions for RNA analysis. This announcement is ...


Page 1 From 11
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE